🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "huge turning point" in the effort against increasingly resistant strains of the pathogen, according to health experts.

An International Challenge

Gonorrhoea infections are escalating globally, with estimates suggesting in excess of 82 million instances annually. Especially elevated rates are reported in Africa and countries within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the context of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options currently available.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Gain Approval

Zoliflodacin, also known as a brand name, was approved by the US FDA in December for treating gonorrhoea. This STI can lead to major issues, including infertility. Researchers believe that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This medication, which is also used to treat urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This approval signifies a significant shift in the therapy of superbug gonorrhoea, which until now has been evolving faster than antibiotic development.”

Testing Data and Global Access

As per findings published in a major medical journal, zoliflodacin cured more than 90% of cases of the STI. This places it at an comparable level with the typical regimen, which uses a dual-drug approach. The research enrolled nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the rights to register and commercialise the drug in many developing nations.

Clinicians treating patients have expressed hope. Having a single-dose, oral treatment such as this is described as a "critical tool" for managing the epidemic. This is viewed as essential to reduce the burden of the disease for people and to halt the transmission of extremely resistant gonorrhoea worldwide.